Participants using tirzepatide lost 22.8 kg and participants on semaglutide lost 15.0 kg SURMOUNT-5 compared tirzepatide, a dual GIP and GLP-1 receptor agonist, to semaglutide, a mono GLP-1 receptor agonist in adults living with obesity without diabetes Eli Lilly and Company (NYSE: LLY) today announced topline results